Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer

Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer

Abstract T cells are important for controlling ovarian cancer (OC). We previously demonstrated that combinatorial use of a personalized whole-tumor lysate-pulsed dendritic cell vaccine (OCDC), bevacizumab (Bev), and cyclophosphamide (Cy) elicited neoantigen-specific T cells and prolonged OC survival...

Full description

Bibliographic Details
Main Authors: Janos L. Tanyi, Cheryl L.-L. Chiang, Johanna Chiffelle, Anne-Christine Thierry, Petra Baumgartener, Florian Huber, Christine Goepfert, David Tarussio, Stephanie Tissot, Drew A. Torigian, Harvey L. Nisenbaum, Brian J. Stevenson, Hajer Fritah Guiren, Ritaparna Ahmed, Anne-Laure Huguenin-Bergenat, Emese Zsiros, Michal Bassani-Sternberg, Rosemarie Mick, Daniel J. Powell, George Coukos, Alexandre Harari, Lana E. Kandalaft
Format: Article
Language:English
Published: Nature Publishing Group 2021-03-01
Series:npj Vaccines
Online Access:https://doi.org/10.1038/s41541-021-00297-5

Internet

https://doi.org/10.1038/s41541-021-00297-5

Similar Items